# EDGAR Filing Document

**Accession Number:** 0001661059
**File Stem:** 0001213900-26-052993
**Filing Date:** 2026-5
**Character Count:** 24083
**Document Hash:** 46fb0afae25769d539440f151ff6ae8f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-052993.hdr.sgml**: 20260506

**ACCESSION NUMBER**: 0001213900-26-052993

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260506

**DATE AS OF CHANGE**: 20260506

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NextCure, Inc.
- **CENTRAL INDEX KEY:** 0001661059
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 475231247
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91004
- **FILM NUMBER:** 26950476

**BUSINESS ADDRESS:**
- **STREET 1:** 9000 VIRGINIA MANOR ROAD, SUITE 200
- **CITY:** BELTSVILLE
- **STATE:** MD
- **ZIP:** 20705
- **BUSINESS PHONE:** 240-399-4900

**MAIL ADDRESS:**
- **STREET 1:** 9000 VIRGINIA MANOR ROAD, SUITE 200
- **CITY:** BELTSVILLE
- **STATE:** MD
- **ZIP:** 20705
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Simcere Zaiming, Inc.
- **CENTRAL INDEX KEY:** 0002080252

**ORGANIZATION NAME:**
- **EIN:** 922412706
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** 20 ACORN PARK DR, CAMBRIDGE, MA 02140
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02140
- **BUSINESS PHONE:** 15049574163

**MAIL ADDRESS:**
- **STREET 1:** 20 ACORN PARK DR, CAMBRIDGE, MA 02140
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02140

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Issuer:** NextCure, Inc.

**Title of Class of Securities:** Common Stock, par value $0.001 per share

**CUSIP Number:** —

**Date of Event Which Requires Filing of this Statement:** 12/31/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Simcere Zaiming, Inc. | Names of Reporting Persons<br>Simcere Zaiming, Inc. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.4% | Percent of Class Represented by Amount in Row (9)<br>9.4% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc.

Note to Row (11): Based on an aggregate of 3,607,555 shares of the Issuer's common stock issued and outstanding as of April 22, 2026 as reported by the Issuer in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.

---

| 1. | Names of Reporting Persons<br>Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. | Names of Reporting Persons<br>Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>F4 | Citizenship or Place of Organization<br>F4 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.4% | Percent of Class Represented by Amount in Row (9)<br>9.4% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. may deemed to beneficially own all of the shares of the Issuer owned by Simcere Zaiming, Inc.

Note to Row (11): Based on an aggregate of 3,607,555 shares of the Issuer's common stock issued and outstanding as of April 22, 2026 as reported by the Issuer in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.

---

| 1. | Names of Reporting Persons<br>Simcere Zaiming Pharmaceutical Co., Ltd. | Names of Reporting Persons<br>Simcere Zaiming Pharmaceutical Co., Ltd. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>F4 | Citizenship or Place of Organization<br>F4 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.4% | Percent of Class Represented by Amount in Row (9)<br>9.4% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which itself is 100% owned by Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, Simcere Zaiming Pharmaceutical Co., Ltd. may deemed to beneficially own all of the shares of the Issuer owned by Simcere Zaiming, Inc.

Note to Row (11): Based on an aggregate of 3,607,555 shares of the Issuer's common stock issued and outstanding as of April 22, 2026 as reported by the Issuer in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.

---

| 1. | Names of Reporting Persons<br>Simcere Pharmaceutical Group Limited | Names of Reporting Persons<br>Simcere Pharmaceutical Group Limited |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>F4 | Citizenship or Place of Organization<br>F4 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.4% | Percent of Class Represented by Amount in Row (9)<br>9.4% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which itself is 100% owned by Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.)  Simcere Pharmaceutical Group Limited is the controlling shareholder of Simcere Zaiming Pharmaceutical Co., Ltd. through investment in several intermediate companies. Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, Simcere Pharmaceutical Group Limited may be deemed to beneficially own all of the shares of the Issuer owned by Simcere Zaiming, Inc.

Note to Row (11): Based on an aggregate of 3,607,555 shares of the Issuer's common stock issued and outstanding as of April 22, 2026 as reported by the Issuer in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.

---

| 1. | Names of Reporting Persons<br>Ren Jinsheng | Names of Reporting Persons<br>Ren Jinsheng |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>F4 | Citizenship or Place of Organization<br>F4 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>338636.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.4% | Percent of Class Represented by Amount in Row (9)<br>9.4% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** Note to Rows (6), (8) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which itself is 100% owned by Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.)  Mr. Jinsheng Ren is the chairman of the board of directors of Simcere Pharmaceutical Group Limited and a director of Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Jinsheng Ren may thereby be deemed to beneficially own the 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., sharing the voting power and investment power over such shares with Mr. Renhong Tang.

Note to Row (11): Based on an aggregate of 3,607,555 shares of the Issuer's common stock issued and outstanding as of April 22, 2026 as reported by the Issuer in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.

---

| 1. | Names of Reporting Persons<br>Tang Renhong | Names of Reporting Persons<br>Tang Renhong |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>F4 | Citizenship or Place of Organization<br>F4 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>338636.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.4% | Percent of Class Represented by Amount in Row (9)<br>9.4% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** Note to Rows (6), (8) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which is 100% owned by Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.)  Mr. Renhong Tang is a director of Simcere Pharmaceutical Group Limited, the chief executive officer and chairman of the board of directors of Simcere Zaiming Pharmaceutical Co., Ltd., a director of Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. and the chief executive officer and sole director of Simcere Zaiming, Inc. Accordingly, Mr. Renhong Tang may thereby be deemed to beneficially own the 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., sharing the voting power and investment power over such shares with Mr. Jinsheng Ren.

Note to Row (11): Based on an aggregate of 3,607,555 shares of the Issuer's common stock issued and outstanding as of April 22, 2026 as reported by the Issuer in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.

---

**Item 1(a). Name of Issuer:**
NextCure, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705

**Item 2(a). Name of Person Filing:**
(i) Simcere Zaiming, Inc., a Delaware corporation ("Simcere Zaiming"), with its principal business address at 20 Acorn Park Dr., Cambridge, MA 02140;

(ii) Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., a limited liability company incorporated in P. R. China ("Jiangsu Zaiming"), is the sole shareholder of Simcere Zaiming, and its principal business address is at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China;

(iii) Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.), a limited liability company incorporated in P. R. China ("Hainan Zaiming"), is the sole shareholder of Jiangsu Zaiming, and its principal business address is at No 20, Yaoguyiheng Road, Xiuying District, Haikou, Hainan, P. R. China;

(iv) Simcere Pharmaceutical Group Limited, a company incorporated in Hong Kong ("Simcere Group") and the controlling shareholder of Hainan Zaiming through several intermediate companies, and its principal business address is at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China;

(v) Mr. Jinsheng Ren, citizen of People's Republic of China, the chairman of board of directors and an executive director of Simcere Group and a director of Hainan Zaiming, with his business address at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China; and

(vi) Mr. Renhong Tang, citizen of People's Republic of China, a director of Simcere Group, the chief executive officer and chairman of the board of directors of Hainan Zaiming, a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming, with his business address at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China.

The persons and entities listed in items (i) to (vi) are collectively referred to herein as "Reporting Persons." The Reporting Persons have entered into a joint filing agreement dated August 19, 2025.

**Item 2(b). Address of Principal Business Office:**
See Item 2(a) above.

**Item 2(c). Citizenship:**
See Item 2(a) above.

**Item 2(d). Title of Class of Securities:**
Common Stock, par value $0.001 per share

**Item 2(e). CUSIP Number:**
—

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

See Row 9 of the cover page for each Reporting Person. Each of Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this Amendment No.1 to Schedule 13G shall not be deemed to be an admission that the Reporting Persons hereunder are the beneficial owners of any of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

**(b) Percent of class:**

See Row 11 of the cover page for each Reporting Person.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

See Row 5 of the cover page for each Reporting Person.

**(ii) Shared power to vote or to direct the vote:**

See Row 6 of the cover page for each Reporting Person.

**(iii) Sole power to dispose or to direct the disposition of:**

See Row 7 of the cover page for each Reporting Person.

**(iv) Shared power to dispose or to direct the disposition of:**

See Row 8 of the cover page for each Reporting Person.

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

—

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Simcere Zaiming, Inc.**

**Date:** 05/06/2026

**By:** /s/ Renhong Tang

**Name & Title:** Renhong Tang/Chief Executive Officer

**Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.**

**Date:** 05/06/2026

**By:** /s/ Renhong Tang

**Name & Title:** Renhong Tang/Director and Attorney-in-Fact

**Simcere Zaiming Pharmaceutical Co., Ltd.**

**Date:** 05/06/2026

**By:** /s/ Renhong Tang

**Name & Title:** Renhong Tang/Chief Executive Officer and Chairman of the Board of Directors

**Simcere Pharmaceutical Group Limited**

**Date:** 05/06/2026

**By:** /s/ Jinsheng Ren

**Name & Title:** Jinsheng Ren/Chairman and Executive Director

**Ren Jinsheng**

**Date:** 05/06/2026

**By:** /s/ Jinsheng Ren

**Name & Title:** Jinsheng Ren

**Tang Renhong**

**Date:** 05/06/2026

**By:** /s/ Renhong Tang

**Name & Title:** Renhong Tang